ICON’s Early Phase team understands the importance and urgency of early phase patient studies to enable go/no-go decisions quickly.
Our flexible operating strategy endorses the Right Site – Right Patient model, and is tailored for small, early-phase patient studies (I-IIA/Proof- of- Concept). With key partnerships and specialised expertise, we can help to mitigate risk and get insight into drug profiles, including safety signals required for decision-making. To access the right patients, we can utilise our internal Phase I clinical research unit, our selective network of trusted partner sites, or other 3rd party sites if they are better suited. This flexibility allows us to customize our strategy for every study to optimize results.
The ICON Early Phase team ensures each trial receives the attention it needs, while being connected to the resources of a large, global CRO. We offer:
- Scientific services
- Flexible models
- Early phase adaptive studies
- Trusted global site network
- PK/PD modelling and simulation
- Early phase biometrics
- Integrated medical writing
We have a proven track record of helping our customers reach key milestones on time, while using cost-effective approaches.
Patient Studies Factsheet
Learn how the ICON Early Phase team can provide customised and flexible solutions.Download Factsheet